Cannabidiol Ameliorates Cognitive Function via Regulation of IL-33 and TREM2 Upregulation in a Murine Model of Alzheimer's Disease

J Alzheimers Dis. 2021;80(3):973-977. doi: 10.3233/JAD-210026.


There is a dire need for due innovative therapeutic modalities to improve outcomes of AD patients. In this study, we tested whether cannabidiol (CBD) improves outcomes in a translational model of familial AD and to investigate if CBD regulates interleukin (IL)-33 and triggering receptor expressed on myeloid cells 2 (TREM2), which are associated with improved cognitive function. CBD was administered to 5xFAD mice, which recapitulate early onset, familial AD. Behavioral tests and immunoassays were used to evaluate cognitive and motor outcomes. Our findings suggest that CBD treatment enhanced IL-33 and TREM2 expression, ameliorated the symptoms of AD, and retarded cognitive decline.

Keywords: Alzheimer’s disease; CBD; ILC2; cannabidiol; dementia; innate lymphoid cells.

Publication types

  • Letter
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Alzheimer Disease / metabolism*
  • Alzheimer Disease / pathology
  • Animals
  • Cannabidiol / pharmacology*
  • Cognition / drug effects*
  • Disease Models, Animal
  • Humans
  • Interleukin-33 / drug effects*
  • Interleukin-33 / metabolism
  • Male
  • Membrane Glycoproteins / drug effects*
  • Membrane Glycoproteins / metabolism
  • Mice
  • Mice, Transgenic
  • Receptors, Immunologic / drug effects*
  • Receptors, Immunologic / metabolism
  • Up-Regulation


  • Interleukin-33
  • Membrane Glycoproteins
  • Receptors, Immunologic
  • Trem2 protein, mouse
  • Cannabidiol